ArticleJournal of clinical laboratory analysis2026
Serum Apelin-13 and Galectin-3 in COVID-19: Associations With Routine Biochemical Parameters and Diagnostic Performance in a Case-Control Study.
Article in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundApelin-13 and Galectin-3 (Gal-3) are bioactive mediators linked to inflammation and cardiometabolic pathways. Their clinical utility in COVID-19 alongside routine laboratory tests remains unclear.
methodsIn this case-control study, 89 adults were enrolled (COVID-19 negative controls, n = 44; COVID-19 positive patients confirmed by PCR and/or CT, n = 45). Serum Apelin-13 and Gal-3 were measured by ELISA, and routine biochemical parameters were obtained using automated analyzers. Group comparisons and correlation analyses were performed, and receiver operating characteristic (ROC) analysis assessed discriminatory performance.
resultsCompared with controls, the COVID-19 group showed higher ALT (p = 0.046), GGT (p = 0.004), ALP (p = 0.001), total bilirubin (p = 0.008), direct bilirubin (p = 0.001), urea (p = 0.001), creatinine (p = 0.001), glucose (p = 0.001), and CRP (p = 0.001), and lower eGFR (p = 0.001), albumin (p = 0.010), and total cholesterol (p = 0.021). In controls, Apelin-13 correlated negatively with urea (r = -0.333, p = 0.027) and Gal-3 correlated negatively with cholesterol (r = -0.342, p = 0.023). In COVID-19 patients, Apelin-13 correlated positively with glucose (r = 0.320, p = 0.032) and negatively with sodium (r = -0.323, p = 0.030). ROC analysis showed limited diagnostic value for Gal-3 (AUC = 0.549; p = 0.426) and Apelin-13 (AUC = 0.533; p = 0.594).
conclusionsApelin-13 and Gal-3 showed limited associations with selected biochemical alterations in COVID-19, but neither biomarker demonstrated adequate standalone discriminatory performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.